Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303.

Xiao-Yan SiLi ZhangHanping WangXiaotong ZhangMengzhao WangBaohui HanKai LiQiming WangJianhua ShiZhehai WangYing ChengYuan-Kai ShiWeiqiang ChenXiuwen WangYi LuoKejun NanFaguang Jin

Published in: Thoracic cancer (2019)

Anlotinb-related adverse events could be controlled by patient education, prophylactic measures, early and active intervention, and dose modification.

Keyphrases

advanced non small cell lung cancer
randomized controlled trial
healthcare
mental health
quality improvement